🔎 Trials Near Me

Pradžia › Ūmi bifeninė leukemija › Oklahoma

Ūmi bifeninė leukemija klinikiniai tyrimai Oklahoma

5 tyrimai dėl Ūmi bifeninė leukemija ieško dalyvių vietose Oklahoma.

Miestai Oklahoma

Oficialus tyrimo tekstas (anglų kalba)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • University of Oklahoma Health Sciences Center, Oklahoma City
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Saint Francis Children's Hospital, Tulsa
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • University of Oklahoma Health Sciences Center, Oklahoma City
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

  • Saint Francis Children's Hospital, Tulsa
Renkami dalyviai2 fazė
Amžius nuo 1 iki 18 · Visoms lytims · Atnaujinta 2026-08-10 · NCT06390319

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

  • Saint Francis Children's Hospital, Tulsa
Renkami dalyviai4 fazė
Amžius nuo 1 iki 18 · Visoms lytims · Atnaujinta 2026-07-14 · NCT06289673

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.